Product image of Micafungin Pharmazac 100 Mg (Micafungin) supplied by GNH India

Micafungin Pharmazac 100 Mg

Active Ingredient:
Micafungin
Origin:
EU

Micafungin Pharmazac 100 Mg (Micafungin)

Micafungin, the active ingredient in Micafungin Pharmazac 100 Mg, is an echinocandin presented as a 100 mg injectable solution for intravenous use. It treats invasive candidiasis, esophageal candidiasis, and is used for prophylaxis of Candida infections in hematopoietic stem cell transplant recipients and for Candida peritonitis and intra‑abdominal infections.

GNH India supplies Micafungin Pharmazac 100 Mg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Pharmazac Sa

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Micafungin is an echinocandin antifungal indicated for several serious Candida infections.

  • Invasive candidiasis: effective treatment of bloodstream and deep‑tissue Candida infections.
  • Esophageal candidiasis: eradicates Candida infection of the esophagus in immunocompromised patients.
  • Prophylaxis in hematopoietic stem cell transplant recipients: prevents Candida infections during the high‑risk transplant period.
  • Candida peritonitis and intra‑abdominal infections: used as part of therapy for intra‑abdominal Candida infections.

How It Works

  • Micafungin inhibits the synthesis of β‑(1,3)‑D‑glucan, an essential component of the fungal cell wall, by binding to the enzyme β‑(1,3)‑D‑glucan synthase. This disruption weakens the cell wall, leading to osmotic instability and cell lysis, which selectively targets Candida species while sparing human cells. Its high affinity for the fungal enzyme and limited oral absorption make intravenous administration the preferred route for systemic infections.

Side Effects

Micafungin may cause a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects

  • Elevated liver enzymes: transient increases in ALT or AST.
  • Fever: mild to moderate temperature rise.
  • Nausea: occasional stomach upset.
  • Phlebitis at infusion site: irritation or redness where the IV is placed.

Serious or Rare Side Effects

  • Hepatotoxicity: significant liver injury requiring monitoring.
  • Severe hypersensitivity reactions: rash, pruritus, or anaphylaxis.
  • Neutropenia: marked reduction in neutrophil count.
  • Renal impairment: acute kidney injury in susceptible patients.

Precautions & Warnings

When using Micafungin, clinicians should observe several precautions to minimize risks and ensure optimal therapy.

  • Liver function monitoring: assess ALT, AST, bilirubin before and during treatment.
  • Renal function assessment: evaluate creatinine clearance in patients with kidney disease.
  • Drug interactions: review concomitant medications that affect hepatic metabolism.
  • Pregnancy and lactation: consider risk‑benefit; use only if clearly needed.
  • Pediatric use: dosage adjustment may be required; follow specialist guidance.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Micafungin can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid)

  • Cyclosporine: increased micafungin exposure may raise toxicity risk.
  • Rifampin: strong enzyme induction can markedly reduce micafungin plasma levels.
  • Antifungal azoles (e.g., fluconazole): may increase micafungin concentrations leading to hepatotoxicity.

Moderate Interactions (Monitor Closely)

  • Warfarin: potential alteration of anticoagulant effect; monitor INR.
  • Statins (e.g., simvastatin): possible increased risk of myopathy; observe muscle symptoms.
  • Immunosuppressants (e.g., tacrolimus): monitor drug levels for possible changes.

Frequently Asked Questions

Micafungin Pharmazac is an injectable echinocandin antifungal indicated for the treatment of invasive candidiasis, esophageal candidiasis, prophylaxis of Candida infections in hematopoietic stem cell transplant recipients, and for Candida peritonitis and intra‑abdominal infections.

Micafungin blocks the enzyme β‑(1,3)‑D‑glucan synthase, preventing the formation of β‑(1,3)‑D‑glucan, a key structural component of the fungal cell wall. This weakens the wall, causing osmotic instability and cell death, while sparing human cells.

The appropriate dose of Micafungin Pharmazac is determined by the prescribing clinician based on the specific infection, patient weight, renal and hepatic function, and other clinical factors. No fixed regimen is provided here.

Micafungin is classified as Pregnancy Category B, indicating that animal studies have not shown risk to the fetus and there are no adequate human studies. It should be used in pregnancy or lactation only if the potential benefit justifies the potential risk.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Micafungin belongs to the echinocandin class, which targets the fungal cell wall, whereas azoles (e.g., fluconazole) inhibit ergosterol synthesis. Echinocandins, including Micafungin, are often preferred for resistant Candida species and have a lower risk of drug‑drug interactions, but they require intravenous administration.

Micafungin Pharmazac should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use to maintain stability.

The product is supplied as a sterile injectable solution for intravenous infusion. It is typically administered over a period of 30‑60 minutes, depending on the prescribed dose and clinical protocol.

Serious adverse events include hepatotoxicity (significant liver enzyme elevation or injury), severe hypersensitivity reactions such as anaphylaxis, neutropenia, and acute renal impairment. Patients should be monitored regularly for these conditions during therapy.

Micafungin is contraindicated in individuals with a known hypersensitivity to micafungin or any component of the formulation. Caution is advised in patients with severe hepatic impairment, and it should be avoided in those with a history of severe allergic reactions to echinocandins.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.